Drug Discovery: Drug Discovery for Small & Large Molecules
ELRIG’s flagship conference, Drug Discovery, has become the largest meeting of life sciences industry professionals in the UK. Now in its 12th year, Drug Discovery 2018 will take place in London’s Excel Arena. This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs.
Our scientific programme will feature over 50 world-class speakers in 8 main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success.
The programme includes scientific poster sessions, coffee/tea and lunch breaks that are located within the vendor exhibition area and a drinks/networking reception on the first day. The meeting is free-of-charge to all delegates and include complimentary refreshments and lunch.
Plenary Keynote Speakers for Drug Discovery 2018
Janet Thornton (European Bioinformatics Institute)
Jonathan Milner (Meltwind)
Day 1 – Tuesday 9th October
Session Chairs – Martin Swarbrick (CRUK TDL) & Nicole Hamblin (Charles River)
Innovations in cellular HTS and compound profiling
Session Chairs – Eddie Stevens (Ario Pharma) & Mark Slack (Evotec)
Anti-infectives & Rare Diseases
Session Chairs – David Brown (Healx Ltd) & Chris Dowson (Warwick University)
Data Sciences and AI
Session Chairs – John Overington (MDC) & Mandy Chessell (IBM)
Day 2 – Wednesday 10th October
Innovations in biochemical and biophysical hit finding techniques
Session Chairs – Geoff Holdgate (AstraZeneca) & Andrew Scott (Concept Life Sciences)
Drug Discovery Networks- Alliances, Partnerships, CRO Relationships and Open Innovation
Session Chairs – Andy Pearce (GlaxoSmithKline) & Julie Frearson (CRL)
Antibodies and Novel Large Molecule Platforms
Session Chairs – David Matthews (LifeArc) & Andy Popplewell (UCB)
Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo)